Septerna, Inc. SEPN

US Pharmaceuticals

$50.74 ▲ +3.87% (+$1.89)

🎢 High Beta

Open $49.86

Prev Close $48.85

Day Range $48.07 – $50.82

52W Range $17.55 – $51.10

Market Cap $2.28B

Beta 0.83

EPS (TTM) $-0.54

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2024-10-25
Shares Out.	46,680,000
Website	septerna.com ↗
Phone	13026587581
Employees	130
Revenue	$26.7M
Gross Profit	$26.7M
Net Income	-$13.0M
Free Cash Flow	$105.1M
Total Assets	$566.7M
Total Liabilities	$180.0M
Equity	$386.7M

About Septerna, Inc.

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna, Inc. is a publicly traded company under the ticker symbol SEPN on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.